← State exam

86. Colon cancer

High yield

Adenocarcinoma from adenomas; right-sided tumours bleed, left-sided obstruct; CT staging, complete mesocolic excision and adjuvant chemotherapy.

Exam Prep · State examSurgery · ColorectalSurgery · Surgical oncology

1. Definition

  • Colon cancer → malignant tumour of the colon, from the caecum to the rectosigmoid junction; over 90% adenocarcinoma
  • Colorectal cancer (CRC) → colon and rectal cancer together; rectal cancer is covered in question 100
  • Others → mucinous adenocarcinoma, signet ring carcinoma, neuroendocrine tumours, lymphoma, GIST, squamous (rare)

2. Epidemiology

  • Third most common cancer worldwide and the second cause of cancer death
  • About two-thirds colon, one-third rectum
  • Age → 90% over 50; median about 70; rising in under-50s (early-onset CRC)
  • Men slightly more than women
  • Site → sigmoid and rectosigmoid most common in the colon; right-sided cancers increasing with age and in women
  • About 20–25% have metastases at diagnosis (liver most often)
  • 5-year survival → stage I about 90%, stage II 80%, stage III 60–70%, stage IV 10–15%
  • Screening finds cancers earlier and removes polyps

3. Aetiology and risk factors

Lifestyle and environment

  • Red and processed meat, low fibre, high fat
  • Obesity, physical inactivity, diabetes
  • Smoking, alcohol
  • Protective → fibre, exercise, aspirin (long-term), calcium, vitamin D

Personal history

  • Adenomatous polyps (size, villous, dysplasia, number) and sessile serrated lesions
  • Previous colorectal cancer
  • Inflammatory bowel disease (UC and Crohn's colitis; duration, extent, PSC)
  • Ureterosigmoidostomy (cancer at the anastomosis)
  • Pelvic radiotherapy, acromegaly, cholecystectomy (weak)
  • Streptococcus bovis (gallolyticus) bacteraemia and endocarditis → look for CRC

Family history and hereditary syndromes (5–10%)

  • First-degree relative → risk doubled (higher if diagnosed under 50)
  • Lynch syndrome (HNPCC) → most common hereditary CRC (about 3%):
    • Mismatch repair (MMR) genes → MLH1, MSH2, MSH6, PMS2, EPCAM
    • Autosomal dominant; right-sided, younger (mean 45), mucinous, many lymphocytes, MSI-high
    • Lifetime CRC risk up to 50–80%; endometrial, ovarian, gastric, small bowel, urinary tract, pancreatic cancers
    • Amsterdam II criteria (3-2-1 rule): 3 relatives with Lynch-associated cancer (one a first-degree relative of the other two), 2 successive generations, 1 diagnosed under 50; FAP excluded
    • Revised Bethesda criteria → which tumours to test for MSI
  • Familial adenomatous polyposis (FAP) → APC gene (chromosome 5q); hundreds to thousands of adenomas by the teens; 100% cancer by 40 without surgery; duodenal adenomas, desmoids, osteomas (Gardner's), brain tumours (Turcot's), CHRPE (retinal pigment)
  • Attenuated FAP (under 100 polyps), MUTYH-associated polyposis (autosomal recessive)
  • Peutz-Jeghers, juvenile polyposis, serrated polyposis syndrome

4. Pathogenesis

Molecular pathways

  • Chromosomal instability (CIN) → about 70–85%: APC → KRAS → SMAD4/DCC (18q) → TP53 (adenoma-carcinoma sequence, Vogelstein); mostly left-sided
  • Microsatellite instability (MSI) → about 15%: MMR deficiency (Lynch: germline; sporadic: MLH1 promoter methylation); right-sided; better prognosis in early stage; responds to immunotherapy
  • Serrated pathway / CIMP → BRAF V600E mutation; sessile serrated lesions; right-sided

Spread

  • Direct → through the bowel wall into the pericolic fat, adjacent organs (bladder, uterus, small bowel, abdominal wall, duodenum, kidney)
  • Lymphatic → epicolic → paracolic → intermediate → central (apical) nodes along the feeding arteries
  • Haematogenous → portal vein → liver (most common; 50% develop liver metastases), then lung; rectal cancer also to the lung through systemic veins
  • Transcoelomic → peritoneal metastases (10–15%), ovaries (Krukenberg), ascites
  • Implantation → anastomosis, wounds, port sites

Right vs left colon cancer

  • Right → exophytic, polypoid, large lumen with liquid stool → anaemia and bleeding, late diagnosis; more MSI, BRAF, older women; worse prognosis in advanced stage
  • Left → annular "apple-core", narrow lumen with solid stool → obstruction, change in bowel habit; more CIN, KRAS

5. Classification

TNM 8th edition

  • Tis → carcinoma in situ, intramucosal (lamina propria)
  • T1 → submucosa
  • T2 → muscularis propria
  • T3 → through the muscularis propria into pericolic tissue
  • T4a → visceral peritoneum; T4b → invades other organs
  • N1 → 1–3 nodes (N1a 1, N1b 2–3, N1c tumour deposits without nodes); N2 → 4 or more (N2a 4–6, N2b 7+)
  • M1a → one organ; M1b → more than one organ; M1c → peritoneum
  • At least 12 lymph nodes must be examined for staging

Stage groups

  • Stage I → T1–T2 N0 M0
  • Stage II → T3–T4 N0 M0
  • Stage III → any T, N1–N2, M0
  • Stage IV → any M1

Dukes' classification (historical, still asked)

  • A → confined to the bowel wall (not beyond the muscularis propria) → 5-year survival about 90%
  • B → through the bowel wall, nodes negative → about 70%
  • C → lymph nodes positive → about 30–60% (C1 apical node free, C2 apical node involved)
  • D → distant metastases (added by Turnbull) → under 10%

Histology

  • Grade → well, moderately, poorly differentiated
  • Mucinous (over 50% mucin), signet ring (poor)
  • Lymphovascular invasion, perineural invasion, tumour budding, extramural venous invasion (EMVI) → adverse features
Table of colon cancer stages, TNM and Dukes
Diagram: colon cancer stages with TNM, Dukes and treatment

6. Clinical picture

Symptoms

  • Change in bowel habit → looser or more frequent stools, or constipation, for weeks (left colon)
  • Rectal bleeding → dark blood mixed with stool (left colon); occult in right colon
  • Iron deficiency anaemia → tiredness, breathlessness (right colon)
  • Abdominal pain, bloating, weight loss, anorexia
  • Tenesmus, mucus (rectosigmoid)
  • Presentation as an emergency in 20–30%:
    • Large bowel obstruction (left-sided tumours; sigmoid most common)
    • Perforation (at the tumour or proximal caecum from closed-loop obstruction)
    • Bleeding (rarely massive)
  • Fistula → pneumaturia (colovesical), faeculent vomiting (gastrocolic)
  • Metastases → RUQ pain, jaundice, ascites

NICE urgent referral (2-week pathway) examples

  • Age 40+ with unexplained weight loss and abdominal pain
  • Age 50+ with unexplained rectal bleeding
  • Age 60+ with iron deficiency anaemia or change in bowel habit
  • Positive FIT (≥ 10 µg Hb/g faeces) with symptoms
  • Abdominal or rectal mass

Signs

  • Often none
  • Pallor (anaemia)
  • Abdominal mass (right iliac fossa in caecal cancer)
  • Hepatomegaly (metastases), ascites, jaundice
  • Rectal examination → low tumours, blood on the glove
  • Distension, high-pitched bowel sounds (obstruction); peritonism (perforation)
  • Virchow's node, Sister Mary Joseph nodule (advanced)

7. Diagnosis

Investigations to diagnose

  • Colonoscopy with biopsy → gold standard; checks the whole colon for synchronous tumours (3–5%) and polyps; tattoo the lesion (for laparoscopic surgery)
  • CT colonography → frail patients, incomplete colonoscopy
  • Flexible sigmoidoscopy → left-sided symptoms
  • FIT → screening and triage of low-risk symptoms

Bloods

  • FBC (microcytic anaemia), ferritin, U&E, LFT
  • CEA → baseline before surgery (prognosis) and follow-up (recurrence); not for diagnosis or screening

Staging

  • CT chest, abdomen and pelvis with contrast → T stage, nodes, liver and lung metastases, peritoneum
  • MRI liver → characterise liver lesions, plan liver surgery
  • PET-CT → selected (recurrence, before metastasectomy, rising CEA)
  • Molecular testing of every tumour → MMR/MSI (Lynch screening, immunotherapy, prognosis), RAS (KRAS, NRAS) and BRAF (anti-EGFR treatment in metastatic disease), HER2
  • Multidisciplinary team decision

Screening (examples)

  • UK → FIT every 2 years from 50 to 74
  • Europe and USA → FIT or colonoscopy every 10 years from 45–50
  • Bulgaria → opportunistic screening; FIT programmes being introduced
  • High risk → colonoscopy surveillance (Lynch every 2 years from 25; FAP yearly flexible sigmoidoscopy from 12–14)
  • Faecal occult blood (guaiac) testing → older, less sensitive

8. Differential diagnosis

  • Diverticular disease (stricture, mass), inflammatory bowel disease
  • Ischaemic colitis, infectious colitis
  • Haemorrhoids (do not blame bleeding on piles without examining the colon in older patients)
  • Irritable bowel syndrome (younger, no alarm features)
  • Appendix mass, ileocaecal TB, lymphoma
  • Other causes of iron deficiency → gastric cancer, coeliac disease, menstrual loss
  • Ovarian cancer (pelvic mass, ascites)
  • Other causes of large bowel obstruction → volvulus, pseudo-obstruction (Ogilvie's), diverticular stricture

9. Treatment

Conservative and systemic

  • Prehabilitation → exercise, nutrition, correct anaemia (IV iron), stop smoking
  • ERAS (enhanced recovery) → no long fasting, carbohydrate drinks, minimal opioids, early feeding and mobilisation
  • Bowel preparation → mechanical bowel preparation with oral antibiotics before elective colectomy lowers surgical site infection and leak (many guidelines)
  • Adjuvant chemotherapy (after resection):
    • Stage III → CAPOX (capecitabine + oxaliplatin) for 3 months (low-risk T1–3 N1) or 6 months (high risk: T4 or N2), or FOLFOX (IDEA collaboration)
    • High-risk stage II (T4, perforation, obstruction, under 12 nodes, lymphovascular invasion, poor differentiation) → consider fluoropyrimidine ± oxaliplatin
    • MSI-high stage II → no adjuvant 5-FU (no benefit; good prognosis)
    • Older patients → capecitabine alone
  • Neoadjuvant chemotherapy → locally advanced colon cancer (T4) on CT (FOxTROT trial: fewer incomplete resections)
  • Neoadjuvant immunotherapy → dMMR / MSI-high tumours → very high response (NICHE-2) (emerging)
  • Metastatic disease:
    • Chemotherapy → FOLFOX, FOLFIRI, CAPOX, FOLFOXIRI
    • Biologics → anti-EGFR (cetuximab, panitumumab) only in RAS wild-type and mainly left-sided tumours; anti-VEGF (bevacizumab)
    • Immunotherapy (pembrolizumab) → first-line for MSI-high / dMMR
    • BRAF V600E → encorafenib + cetuximab; HER2 → targeted therapy
    • Conversion chemotherapy → may make liver metastases resectable
  • Palliative care → symptom control, stents, best supportive care

Surgical: elective colectomy

  • Principles of oncological resection:
    • Resect the tumour with its lymphatic field → divide the feeding artery at its origin (high tie)
    • Complete mesocolic excision (CME) with central vascular ligation (CVL) → dissect in the embryological plane and remove the mesocolon intact (Hohenberger); more nodes, possibly better survival
    • Clear margins → at least 5 cm of bowel on each side; en bloc resection of any adherent organ (T4b; adhesions may be tumour)
    • At least 12 nodes
    • No-touch technique (debated), protect the wound
    • Laparoscopic surgery → same cancer results as open (CLASICC and COST trials), faster recovery; robotic in some centres
  • Operations by tumour site:
    • Caecum, ascending colon, hepatic flexure → right hemicolectomy (ileocolic, right colic and right branch of the middle colic vessels); ileocolic anastomosis
    • Transverse colon → extended right hemicolectomy (middle colic at origin) or transverse colectomy
    • Splenic flexure → extended right hemicolectomy or left hemicolectomy (segmental splenic flexure resection in selected cases)
    • Descending colon → left hemicolectomy (inferior mesenteric artery or left colic artery)
    • Sigmoid colon → sigmoid colectomy / high anterior resection (IMA ligated at origin, often with splenic flexure mobilisation)
    • Multiple tumours, Lynch syndrome, FAP → subtotal or total colectomy (± proctectomy)
  • Anastomosis → stapled or hand-sewn; tension-free, good blood supply (ICG fluorescence angiography in some centres), no distal obstruction
  • Defunctioning stoma → rarely needed in colon surgery (more in low rectal anastomoses)

Surgical: emergency presentations

  • Obstructing right-sided cancer → right or extended right hemicolectomy with primary anastomosis (or end ileostomy if unstable)
  • Obstructing left-sided cancer:
    • Resection with primary anastomosis ± defunctioning ileostomy in fit, stable patients (with or without on-table lavage)
    • Hartmann's procedure → unstable, frail, faecal peritonitis
    • Subtotal colectomy with ileorectal anastomosis → caecal ischaemia or perforation, or synchronous tumours
    • Self-expanding metal stent → bridge to surgery (convert emergency to elective; risk of perforation and tumour seeding) or palliation in incurable disease
    • Loop colostomy or ileostomy → palliation or to allow neoadjuvant treatment
  • Perforation → resection of the tumour (Hartmann's commonly), washout; worse prognosis (seeding)
  • Bleeding → resection once stable; embolisation rarely

Surgical: metastatic and recurrent disease

  • Liver metastases → resection if all disease can be removed with clear margins and enough future liver remnant (5-year survival 40–50%); synchronous or staged (liver-first) approaches; ablation for small lesions; portal vein embolisation
  • Lung metastases → resection (metastasectomy) in selected patients
  • Peritoneal metastases → cytoreductive surgery (± HIPEC) in selected patients with low peritoneal cancer index
  • Primary tumour in incurable disease → resect only if symptomatic (obstruction, bleeding, perforation)

Follow-up

  • CEA every 3–6 months and CT chest, abdomen and pelvis at intervals for 3–5 years
  • Colonoscopy at 1 year after surgery (or within 6 months if the colon was not fully seen before), then at 3 and 5 years by findings
Flowchart of the management of colon cancer
Diagram: colon cancer, from diagnosis to resection and chemotherapy

10. Complications

Of the cancer

  • Large bowel obstruction → caecal perforation if the ileocaecal valve is competent (closed loop)
  • Perforation, peritonitis, abscess
  • Bleeding, anaemia
  • Fistula (colovesical, colovaginal, gastrocolic, enteric)
  • Invasion of nearby organs; ureteric obstruction
  • Metastases → liver failure, jaundice, ascites, lung
  • Cachexia

Of surgery

  • Anastomotic leak → about 2–4% (right side), 5–10% (left side and low anastomoses); days 3–7; sepsis, peritonitis, ileus
  • Surgical site infection, intra-abdominal abscess
  • Bleeding, ileus (most common), small bowel obstruction
  • Ureteric injury (left colectomy, sigmoid), splenic injury (splenic flexure), duodenal injury (right hemicolectomy)
  • Incisional hernia, parastomal hernia
  • VTE, pneumonia, cardiac events
  • Bowel dysfunction (diarrhoea after right hemicolectomy, bile acid malabsorption)
  • Low anterior resection syndrome (after sigmoid and rectal resections)

Of chemotherapy

  • Oxaliplatin → peripheral neuropathy (cold-induced), may be permanent
  • Capecitabine and 5-FU → hand-foot syndrome, diarrhoea, mucositis, DPD deficiency (test before starting: severe toxicity)
  • Irinotecan → diarrhoea, neutropenia
  • Cetuximab → acneiform rash; bevacizumab → bleeding, perforation, poor wound healing

Mind map Pinch or scroll to zoom · drag to move

Show as a list

Colon cancer

  • Risk
    • Age, diet, obesity
    • Adenomas
    • IBD
    • Lynch: MMR, 3-2-1
    • FAP: APC
  • Pathways
    • CIN: APC, KRAS, p53
    • MSI: MMR
    • Serrated: BRAF
  • Clinical
    • Right: anaemia, mass
    • Left: obstruction, bleeding
    • Emergency 20-30%
  • Tests
    • Colonoscopy + biopsy
    • CT chest, abdomen, pelvis
    • CEA baseline
    • MMR, RAS, BRAF
  • Staging
    • TNM: I-IV
    • Dukes A-D
    • 12 nodes
  • Surgery
    • Right hemicolectomy
    • Extended right
    • Left hemicolectomy
    • Sigmoid colectomy
    • CME, high tie
    • Laparoscopic
  • Emergency
    • Hartmann's
    • Stent as bridge
  • Chemotherapy
    • Stage III: CAPOX, FOLFOX
    • High-risk stage II
    • Metastatic: anti-EGFR if RAS wild
    • MSI-high: pembrolizumab
  • Metastases
    • Liver resection
    • Lung resection
    • CRS +/- HIPEC

More in State exam